Retatrutide
Phase 3 obesity data positive; BLA submission planned for Q1 2027.
What it is
A triple GIP, GLP-1 and glucagon receptor agonist injection in late-stage development for obesity and related conditions. Lilly says the clinical data package for obesity is now complete.
Why it matters to the stock. Retatrutide is the next incretin leg of Lilly's obesity strategy and the biggest pipeline catalyst after Foundayo; its filing timing and efficacy versus Zepbound will drive the medium-term outlook.
News
Retatrutide TRIUMPH-2 detail: 20.8% weight loss at 12 mg, published in The Lancet
Lilly presented detailed TRIUMPH-2 results for retatrutide at the EASD meeting in Milan on September 29, 2026, with a simultaneous Lancet publication.
Lilly Q2 2026 revenue rises 48% to $22.97B; 2026 revenue guidance raised to $85-87B
Lilly reported second-quarter 2026 revenue of $22,974 million, up 48%, driven by volume growth of 60% that more than offset a 13% drop in realized prices.
Retatrutide Phase 3 TRIUMPH-2 and TRIUMPH-3 positive; up to 22.6% weight loss
Lilly reported positive topline results from two Phase 3 trials of retatrutide, its triple GIP, GLP-1 and glucagon agonist.
Retatrutide meets primary endpoints in TRIUMPH-2 and TRIUMPH-3
Lilly reported that retatrutide met the primary endpoint in two more Phase 3 obesity trials: TRIUMPH-2 in adults with obesity and type 2 diabetes, and TRIUMPH-3 in adults with severe obesity and cardiovascular disease.
Retatrutide hits 25% weight loss at 80 weeks in TRIUMPH-1 Phase 3
Lilly reported topline results from TRIUMPH-1, a Phase 3 obesity trial of retatrutide, a triple GIP, GLP-1 and glucagon receptor agonist.